Free Trial

Trading of Spruce Biosciences was halted at 10:38 AM EST due to "LULD pause".

NASDAQ:SPRB

Spruce Biosciences (SPRB) Stock Price, News & Analysis

Spruce Biosciences logo
$36.73 +27.91 (+316.49%)
As of 11:10 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Spruce Biosciences Stock (NASDAQ:SPRB)

Advanced

Key Stats

Today's Range
$30.03
$47.30
50-Day Range
$7.00
$12.40
52-Week Range
$4.28
$47.30
Volume
18.38 million shs
Average Volume
99,371 shs
Market Capitalization
$20.23 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$131.25
Consensus Rating
Reduce

Company Overview

Spruce Biosciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
31st Percentile Overall Score

SPRB MarketRank™: 

Spruce Biosciences scored higher than 31% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Spruce Biosciences has received a consensus rating of Reduce. The company's average rating score is 1.86, and is based on no buy ratings, 6 hold ratings, and 1 sell rating.

  • Upside Potential

    Spruce Biosciences has a consensus price target of $131.25, representing about 1,550.9% upside from its current price of $7.95.

  • Amount of Analyst Coverage

    Spruce Biosciences has only been the subject of 1 research reports in the past 90 days.

  • Read more about Spruce Biosciences' stock forecast and price target.
  • Earnings Growth

    Earnings for Spruce Biosciences are expected to grow in the coming year, from ($1.00) to ($0.85) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Spruce Biosciences is -0.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Spruce Biosciences is -0.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Spruce Biosciences has a P/B Ratio of 0.15. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Spruce Biosciences' valuation and earnings.
  • Short Interest

    There is no current short interest data available for SPRB.
  • Dividend Yield

    Spruce Biosciences does not currently pay a dividend.

  • Dividend Growth

    Spruce Biosciences does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for SPRB.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Spruce Biosciences this week, compared to 0 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Spruce Biosciences insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 6.90% of the stock of Spruce Biosciences is held by insiders.

  • Percentage Held by Institutions

    91.71% of the stock of Spruce Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Spruce Biosciences' insider trading history.
Receive SPRB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Spruce Biosciences and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

SPRB Stock News Headlines

What Steve Bannon revealed about Trump’s gold play
A Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your IRA could be at risk. Here’s how to prepare.tc pixel
Analysts Set Spruce Biosciences, Inc. (NASDAQ:SPRB) PT at $131.25
Spruce Biosciences Resumes Trading on the Nasdaq Capital Market
See More Headlines

SPRB Stock Analysis - Frequently Asked Questions

Spruce Biosciences' stock was trading at $31.50 at the start of the year. Since then, SPRB shares have decreased by 74.8% and is now trading at $7.95.

Spruce Biosciences, Inc. (NASDAQ:SPRB) announced its quarterly earnings results on Tuesday, April, 15th. The company reported ($42.75) earnings per share for the quarter, missing analysts' consensus estimates of ($15.00) by $27.75. The firm had revenue of $0.55 million for the quarter, compared to analysts' expectations of $0.50 million.

Shares of Spruce Biosciences reverse split on Monday, August 4th 2025.The 1-75 reverse split was announced on Thursday, July 24th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 1st 2025. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

Spruce Biosciences (SPRB) raised $75 million in an initial public offering (IPO) on Friday, October 9th 2020. The company issued 5,000,000 shares at $14.00-$16.00 per share. Cowen, SVB Leerink, Credit Suisse and RBC Capital Markets acted as the underwriters for the IPO.

Shares of SPRB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Spruce Biosciences investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Jabil (JBL), Adobe (ADBE), Meta Platforms (META) and Disc Medicine (IRON).

Company Calendar

Last Earnings
4/15/2025
Today
10/05/2025
Next Earnings (Estimated)
11/10/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:SPRB
CIK
1683553
Fax
N/A
Employees
20
Year Founded
2016

Price Target and Rating

High Price Target
$225.00
Low Price Target
$37.50
Potential Upside/Downside
+1,550.9%
Consensus Rating
Reduce
Rating Score (0-4)
1.86
Research Coverage
7 Analysts

Profitability

EPS (Trailing Twelve Months)
($86.21)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$53.04 million
Net Margins
N/A
Pretax Margin
-3,721.17%
Return on Equity
-177.45%
Return on Assets
-118.06%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.60
Quick Ratio
2.60

Sales & Book Value

Annual Sales
$4.91 million
Price / Sales
0.91
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$52.47 per share
Price / Book
0.15

Miscellaneous

Outstanding Shares
560,000
Free Float
523,000
Market Cap
$4.45 million
Optionable
Optionable
Beta
2.47

Social Links

The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

This page (NASDAQ:SPRB) was last updated on 10/6/2025 by MarketBeat.com Staff
From Our Partners